Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
Immunoadsorption
Immunoadsorption is a procedure that removes specific blood group antibodies from the blood.[1] It is needed to remove the antibodies against pathogenic antibodies.[2][3][4]
The procedure generally takes about three to four hours.[5]
Immunoadsorption was developed in the 1990s as a method of extracorporeal removal of molecules from the blood, in particular molecules of the immune system.
Different number of devices/columns exist on the market, each with a different active component to which the molecule of interest attaches, allowing for selectivity in the molecules of interest.[citation needed]
Immunoadsorption may be used as an alternative to plasma exchange in certain conditions.[6] Evidence of benefit is lacking in those with kidney problems. Concerns include that it is expensive.[7]
- ^ Koziolek, Michael J; Tampe, Desiree; Bähr, Matthias; Dihazi, Hassan; Jung, Klaus; Fitzner, Dirk; Klingel, Reinhard; Müller, Gerhard A; Kitze, Bernd (2012). "Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis". Journal of Neuroinflammation. 9: 80. doi:10.1186/1742-2094-9-80. PMC 3418188. PMID 22537481.
- ^ Ikeda, Uichi; Kasai, Hiroki; Izawa, Atsushi; Koyama, Jun; Yazaki, Yoshikazu; Takahashi, Masafumi; Higuchi, Makoto; Koh, Chang-Sung; Yamamoto, Keiji (2008). "Immunoadsorption Therapy for Patients with Dilated Cardiomyopathy and Heart Failure". Current Cardiology Reviews. 4 (3): 219–22. doi:10.2174/157340308785160534. PMC 2780823. PMID 19936198.
- ^ Hohenstein, B.; Bornstein, S.R.; Aringer, M. (2013). "Immunoadsorption for connective tissue disease". Atherosclerosis Supplements. 14 (1): 185–9. doi:10.1016/j.atherosclerosissup.2012.10.034. PMID 23357163.
- ^ Terman, Davids.; Buffaloe, George; Cook, Gary; Sullivan, Michael; Mattioli, Carlos; Tillquist, Richard; Carlos Ayus, Juan (1979). "Extracorporeal Immunoadsorption: Initial Experience in Human Systemic Lupus Erythematosus". The Lancet. 314 (8147): 824–827. doi:10.1016/S0140-6736(79)92177-9. PMID 90920. S2CID 45206606.
- ^ Yadav, Satyen. "University Hospital Birmingham, Immunoasorption" (PDF). Archived from the original (PDF) on 2011-11-09. Retrieved 2021-06-29.
- ^ Kronbichler, A; Brezina, B; Quintana, LF; Jayne, DR (January 2016). "Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review". Autoimmunity Reviews. 15 (1): 38–49. doi:10.1016/j.autrev.2015.08.010. PMID 26318215.
- ^ Dorst, Johannes; Fillies, Frank; Dreyhaupt, Jens; Senel, Makbule; Tumani, Hayrettin (September 2020). "Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases". Journal of Clinical Medicine. 9 (9): 2874. doi:10.3390/jcm9092874. PMC 7565027. PMID 32899499.
Previous Page Next Page
